Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

8.360 +0.290 (+3.59%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	379,288
Open	8.000
Bid (Size)	8.360 (400)
Ask (Size)	8.380 (100)
Prev. Close	8.070
Today's Range	7.950 - 8.510
52wk Range	1.340 - 8.970
Shares Outstanding	33,577,873
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

January 28, 2026

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗

January 12, 2026

Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.

Via Benzinga

Performance

YTD	+54.0%	+54.0%
1 Month	+43.4%	+43.4%
3 Month	+107.4%	+107.4%
6 Month	+266.7%	+266.7%
1 Year	+416.0%	+416.0%

More News

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

December 09, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗

December 08, 2025

Via Stocktwits

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

December 07, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

December 07, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 12, 2025

Via Benzinga

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

November 12, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 07, 2025

Via Benzinga

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

November 03, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

October 14, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

October 06, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

October 01, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

September 18, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

September 11, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 08, 2025

Via Benzinga

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

September 08, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

August 25, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Announces Other Serious Diseases Strategy

August 06, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

July 11, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

July 07, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Attends FDA CEO Forum in Washington DC

June 06, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

June 03, 2025

From Immix Biopharma, Inc.

Via GlobeNewswire

The trading volume of these stocks is deviating from the norm in today's session. ↗

May 29, 2025

Via Chartmill

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

May 27, 2025

Via Chartmill

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?

Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Immix Biopharma, Inc. - Common Stock trade on?

Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?

The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market

What is the current price of Immix Biopharma, Inc. - Common Stock?

The current price of Immix Biopharma, Inc. - Common Stock is 8.360

When was Immix Biopharma, Inc. - Common Stock last traded?

The last trade of Immix Biopharma, Inc. - Common Stock was at 03/02/26 04:00 PM ET

What is the market capitalization of Immix Biopharma, Inc. - Common Stock?

The market capitalization of Immix Biopharma, Inc. - Common Stock is 280.71M

How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?

Immix Biopharma, Inc. - Common Stock has 281M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.